MedTrace Logo

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

NCT04467723 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-01-28

No results posted yet for this study

Summary

The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.

Conditions

  • NSCLC Stage IV
  • NSCLC, Recurrent

Interventions

DRUG

Atezolizumab

Atezolizumab is given as an intravenous infusion at 1200 mg every 3 weeks. Pirfenidone is taken by mouth 3 times a day with the dose increasing every 2 week until day 30

Sponsors & Collaborators

  • parkview cancer institute

    collaborator UNKNOWN

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Chao Huang, MD · The University of Kansas

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-18
Primary Completion
2027-01-01
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04467723 on ClinicalTrials.gov